Drawing on the example of several successful conjugates of glucose utilized in hematologic cancer treatment [24,25,26], with their favorable pharmacokinetic and safety profile, a functional Glu–MTX conjugate could offer the prospect of highly successful therapy in GLUT-abundant hematologic malignancies that might also be used readily in combination with other modalities to improve clinical outcomes. The gene discussed is SLC2A1; the disease is hematopoietic and lymphoid cell neoplasm.